| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6636b59c3149a23a6ae7feaa3984d05f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0e232a0531450d3008474d82113f478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77f8d38b65aca630c0160a482d062207
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd3a84dc050d9eb000ee6708d6e925a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b57ba4940a83009b4b5a4064c4b90e36 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-342 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
| filingDate |
2011-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b01432e214fd04889ebb841edfc40b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d08224f6007204cc52248cc8d7f5155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6965a5b94bc8986df642a45606fa68e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0513cf7a530fdf7ccbb30d6d093bce49 |
| publicationDate |
2017-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9561196-B2 |
| titleOfInvention |
Methods for evaluating and implementing prostate disease treatments |
| abstract |
Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia. The method comprises initiating androgen deprivation in the individual and administering to the individual an agent capable of inducing apoptosis of vascular endothelial cells within a period of 1-7 days of initiating androgen deprivation. |
| priorityDate |
2007-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |